Table 1 Baseline relative risks of disease due to alcohol consumption
From: Cost-effectiveness of changes in alcohol taxation in Denmark: a modelling study
| Â | Â | Alcohol intake level a | Â | |||
|---|---|---|---|---|---|---|
Disease | Sex | Abstinence | Low | Hazardous | Harmful | Source |
Ischaemic heart disease (15–34 yr) | Male | 0.95 (0.83–1.08) | 0.64 (0.17–1.47) | 0.56 (0.17–1.19) | 1.00 | Roerecke and Rehm, [34] |
Female | 0.93 (0.89–0.97) | 0.34 (0.12–0.67) | 0.34 (0.06–0.87) | 1.01 (0.05–4.69) | ||
Ischaemic heart disease (35–64 yr) | Male | 0.97 (0.90–1.04) | 0.75 (0.38–1.23) | 0.70 (0.37–1.10) | 1.00 | Roerecke and Rehm, [34] |
Female | 0.96 (0.94–0.98) | 0.53 (0.31–0.77) | 0.51 (0.21–0.90) | 0.87 (0.20–2.36) | ||
Ischaemic heart disease (65 + yr) | Male | 1.00 (0.96–1.03) | 0.99 (0.64–1.39) | 0.98 (0.62–1.42) | 1.00 | Roerecke and Rehm, [34] |
Female | 1.00 (0.97–1.03) | 0.99 (0.54–1.66) | 1.00 (0.46–1.86) | 1.02 (0.50–1.75) | ||
Ischaemic stroke | Male | 1.00 | 0.87 (0.81–0.93) | 0.97 (0.90–1.04) | 1.24 (1.12–1.37) | Patra et al., [2] |
Female | 1.00 | 0.84 (0.76–0.91) | 0.84 (0.74–0.94) | 0.98 (0.86–1.12) | ||
Hemorrhagic stroke | Male | 1.00 | 1.10 (1.06–1.14) | 1.27 (1.15–1.40) | 1.77 (1.40–2.20) | Patra et al., [2] |
Female | 1.00 | 0.66 (0.52–0.83) | 0.76 (0.57–0.99) | 1.13 (0.81–1.54) | ||
Hypertensive heart disease | Male | 1.00 | 1.12 (1.09–1.14) | 1.33 (1.25–1.41) | 1.95 (1.69–2.24) | Taylor et al., [1] |
Female | 1.00 | 0.80 (0.69–0.92) | 1.15 (0.89–1.45) | 2.39 (1.61–3.42) | ||
Pancreatitis | Male | 1.00 | 1.02 (1.02–1.03) | 1.16 (1.12–1.20) | 2.26 (1.88–2.69) | Irving et al., [3] |
Female | 1.00 | 1.01 (1.01–1.01) | 1.05 (1.04–1.07) | 1.34 (1.25–1.34) | ||
Cirrhosis | Male | 1.00 | 1.23 (1.17–1.28) | 1.70 (1.51–1.90) | 3.49 (2.63–4.53) | Rehm et al., [4] |
Female | 1.00 | 1.82 (1.63–2.04) | 2.76 (2.27–3.32) | 4.81 (3.55–6.35) | ||
Breast cancer | Male | – | – | – | – | Corrao et al., [6] |
Female | 1.00 | 1.06 (1.05–1.07) | 1.17 (1.14–1.21) | 1.47 (1.38–1.57) | ||
Mouth and oropharynx cancer | Male | 1.00 | 1.37 (1.33–1.41) | 2.13 (2.00–2.27) | 4.58 (4.13–5-06) | Corrao et al., [6] |
Female | 1.00 | 1.18 (1.16–1.20) | 1.59 (1.53–1.66) | 2.77 (2.55–2.99) | ||
Oesophagus cancer | Male | 1.00 | 1.17 (1.16–1.18) | 1.51 (1.47–1.54) | 2.59 (2.45–2.74) | Corrao et al., [6] |
Female | 1.00 | 1.09 (1.08–1.09) | 1.27 (1.26.1.29) | 1.78 (1.72–1.84) | ||
Liver cancer | Male | 1.00 | 1.09 (1.06–1.12) | 1-24 (1.15–1-34) | 1.59 (1.36–1.85) | Corrao et al., [6] |
Female | 1.00 | 1.05 (1.03–1.06) | 1.14 (1.09–1.19) | 1.35 (1.22–1.49) | ||
Larynx cancer | Male | 1.00 | 1.19 (1.17–1.21) | 1.55 (1.49–1.62) | 2.76 (2.50–3.03) | Corrao et al., [6] |
Female | 1.00 | 1.09 (1.08–1.10) | 1.30 (1.26–1.33) | 1.85 (1.75–1.97) | ||
Colon cancer | Male | 1.00 | 1.02 (1.01–1.04) | 1.06 (1.02–1.11) | 1.15 (1.04–1.27) | Corrao et al., [6] |
Female | 1.00 | 1.01 (1.00–1.02) | 1.04 (1.01–1.06) | 1.09 (1.03–1.15) | ||
Rectal cancer | Male | 1.00 | 1.04 (1.03–1.05) | 1.12 (1.09–1.15) | 1.29 (1.21–1.38) | Corrao et al., [6] |
Female | 1.00 | 1.02 (1.02–1.03) | 1.07 (1.05–1.08) | 1.17 (1.12–1.21) | ||